Alps Group Inc · NASDAQ:ALPS
Alps — Alps Global Holding Berhad — Investor Presentation (May 2018)
52 slides from Alps's investor presentation, May 30, 2018
Slide 1: Alps Global Holding Berhad
ALPS GLOBAL HOLDING BERHAD (Company No. 1227032V) (Updated as at 30th May 2018)
Slide 2: The mystery of Genetics
The mystery of Genetics
Slide 3: Importance of the industry and Future Developments
Importance of the industry and Future Developments
Slide 4: Biomarkers for Precision Medicine
Precision Medicine Biomarkers for Cancer Detection
Slide 5: mRNA Genetic Therapy
Precision Medicine mRNA Genetic Therapy
Slide 6: Healthy Aging Stem Cell Therapy
Preventive Medicine Healthy Aging Stem Cell Therapy
Slide 7: What is Stem Cell Therapy?
What is Stem Cell Therapy?
Slide 8: Benefits of Stem Cell Therapy
Benefits of Stem Cell Therapy
Slide 9: Repairs Damage Cells & Regenerates New Cells
Repairs Damage Cells & Regenerates New Cells
Slide 10: Slide 10
Slide 11: There are various cell-related products in the market
There are various "cell-related” products in the market
Slide 12: But not all products consist Stem Cells
But not all products consist Stem Cells
Slide 13: Stem Cells must be stored under -196°C Liquid Nitrogen Storage
Stem Cells must be stored under - 196°C Liquid Nitrogen Storage
Slide 14: ALPS - an Ethical Life Science company
ALPS-an Ethical Life Science company
Slide 15: Mastering the technique of Genetic Modification
Mastering the technique of Genetic Modification
Slide 16: New Chapter for a Revitalized Humanity
New Chapter for a Revitalized Humanity
Slide 17: Alps Medical Centre
Malaysia Healthcare Trael Council Member of Alps Medical Centre Ministry of Health, Malaysia since 2016 Licensed Private Ambulatory Care Centre Under Private Healthcare Facilities and Services Act 1998
Slide 18: Slide 18
Slide 19: Slide 19
Slide 20: Slide 20
Slide 21: Slide 21
Slide 22: Slide 22
Slide 23: Alps Medical Clinic (Genting Highlands)
Alps Medical Clinic (Genting Highlands)
Slide 24: Alps Wellness Centre (Genting Highlands)
Alps Wellness Centre (Genting Highlands)
Slide 25: a SR Ss
a SR Ss a ALPS \ wv
Slide 26: Slide 26
Slide 27: Ethical Life Science
(74 4\LPS ETHICAL LIFE SCIENCE
Slide 28: =) pee |
4 =) pee | ty Sei... “re boat TIFE seremce t
Slide 29: Ethical Life Science
a \ NLPS ETHICAL LIFE SCIENCE
Slide 30: Asia's First Anti-Aging Centre located in Highlands
Asia’s First Anti-Aging Centre located in Highlands
Slide 31: Slide 31
Slide 32: Successful Testimonials
Successful Testimonials
Slide 33: Stem Cells to treat diseases
ETHICAL LIFE SCIENCE Stem Cells to treat diseases ° 2
Slide 34: Type of Diseases curable by Stem Cells
Type of Diseases curable by Stem Cells
Slide 35: Medical Breakthrough
ETHICAL LIFE SCIENCE Medical Breakthrough
Slide 36: Precision Medicine
Precision Medicine
Slide 37: New Chapter for Revitalized Humanity
New Chapter for Revitalized Humanity
Slide 38: Integrated global Medical Scientists
Integrated global Medical Scientists
Slide 39: Corporate Structure
Corporate Structure GROUP Marketing Healthcare Laboratory Trading / Distribution Education Investments Insurance cGMP® * To be established MOON LITE (M) EDU MED in 2020 ALSCAP BHD SB BHD * To be established in 2019 GLP® Strategic Alliances CELEBRE DEGEN MED RESORT SB P REMIE R LAB OR A TORY BHD * To
Slide 40: Borderless Research Centres
Borderless Research Centres
Slide 41: Continuous Research & Development
Continuous Research & Development
Slide 42: Attracts the BEST scientists in the world
Attracts the BEST scientists in the world
Slide 43: Collaborations with World-Class Research Centres
Collaborations with World-Class Research Centres
Slide 44: a FAIR Medical System
a FAIR Medical System
Slide 45: Team's Vision towards IPO
Team’s Vision towards IPO
Slide 46: Our OWN Stem Cell Research & Production
Our OWN Stem Cell Research & Production
Slide 47: Our Founders
ETHICAL LIFE SCIENCE
Slide 48: Dedicated Management Team
Dedicated Management Team
Slide 49: Financial Road Map
ETHICAL LIFE SCIENCE
Slide 50: Financial Road Map
Financial Road Map Profit Forecast (USD) P/E ratio Valuation (USD) Share Proceed (USD) Round 1 - - 310,000,000 31,000,000 Round 2 - - 700,000,000 56,000,000 Round 3 - - 1,600,000,000 80,000,000 Round 4 211,764,706 17 3,600,000,000 180,000,000 Round 5 320,000,000 25 8,000,000,000 200,000,000 Round 6
Slide 51: Forecast and ROI (Business Model 1)
Forecast and ROI (Business Model 1) Estimated Period: 36 months to 60 months Estimated Market Estimated Expense/ P/E Ratio KPI ROI Cap People Person (USD) 40 250m 10B 10-20x 250k 1000 40 500m 20B 20-40x 500k 1000 40 1B 40B 40-80x 1m 1000 40 2B 80B 80-160x 2m 1000 Pre-IPO 160B 160-320x
Slide 52: Alps Global Holding Berhad
谢谢 ALPS GLOBAL HOLDING BERHAD (Company No. 1227032V) For Further Information please contact: Investor Relations Department Tel: +603 7982 7979 Email: investorrelations@alpsmedical.com
Alps Global Holding Berhad — Investor Presentation (May 2018) on 6ix